Market open
Kezar Life Sciences/$KZR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kezar Life Sciences
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Ticker
$KZR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
55
Website
KZR Metrics
BasicAdvanced
$30M
-
-$11.49
0.61
-
Price and volume
Market cap
$30M
Beta
0.61
52-week high
$7.47
52-week low
$3.62
Average daily volume
26K
Financial strength
Current ratio
6.763
Quick ratio
6.526
Long term debt to equity
6.361
Total debt to equity
13.839
Interest coverage (TTM)
-55.95%
Management effectiveness
Return on assets (TTM)
-30.45%
Return on equity (TTM)
-55.00%
Valuation
Price to book
0.26
Price to tangible book (TTM)
0.26
Price to free cash flow (TTM)
-0.404
Growth
Earnings per share change (TTM)
-18.19%
3-year earnings per share growth (CAGR)
3.52%
KZR News
AllArticlesVideos
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
Seeking Alpha·3 weeks ago
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kezar Life Sciences stock?
Kezar Life Sciences (KZR) has a market cap of $30M as of April 16, 2025.
What is the P/E ratio for Kezar Life Sciences stock?
The price to earnings (P/E) ratio for Kezar Life Sciences (KZR) stock is 0 as of April 16, 2025.
Does Kezar Life Sciences stock pay dividends?
No, Kezar Life Sciences (KZR) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Kezar Life Sciences dividend payment date?
Kezar Life Sciences (KZR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kezar Life Sciences?
Kezar Life Sciences (KZR) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.